Company intelligence / Profile preview

KNOW Bio

Durham, North Carolina, United Statesknowbiollc.com ↗

Ownership: Public · KNW
Employees: ~12
Development stage: Preclinical

Overview

The company has shown efficacy in both in vitro lab testing and in animal models, including the ability to eradicate Pseudomonas aeruginosa from the sputum of cystic fibrosis patients[5]. They have eradicated 29 strains of Pseudomonas aeruginosa in testing[5].

Therapeutic areas: GastroenterologyInfectious Diseases
Modalities: Nitric oxide-based therapeuticsPrecision light therapy
Industry: Biotech

Partnerships

Unnamed large pharma partner[2]

Financials

Market cap: $16.1M
Total revenue: $0
Enterprise value: $-2.8B

Beyond the preview

Go deeper on KNOW Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KNOW Bio.

Explore the full profile